Interplay Between the Immune and Endocrine Systems in the Lung: Implications for TB Susceptibility

Tariq Webber¹, Katharina Ronacher², Marli Conradie-Smit³ and Léanie Kleynhans¹*

¹ DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa, ² Translational Research Institute, Mater Research Institute – The University of Queensland, Brisbane, QLD, Australia, ³ Division of Endocrinology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

The role of the endocrine system on the immune response, especially in the lung, remains poorly understood. Hormones play a crucial role in the development, homeostasis, metabolism, and response to the environment of cells and tissues. Major infectious and metabolic diseases, such as tuberculosis and diabetes, continue to converge, necessitating the development of a clearer understanding of the immune and endocrine interactions that occur in the lung. Research in bacterial respiratory infections is at a critical point, where the limitations in identifying and developing antibiotics is becoming more profound. Hormone receptors on alveolar and immune cells may provide a plethora of targets for host-directed therapy. This review discusses the interactions between the immune and endocrine systems in the lung. We describe hormone receptors currently identified in the lungs, focusing on the effect hormones have on the pulmonary immune response. Altered endocrine responses in the lung affect the balance between pro- and anti-inflammatory immune responses and play a role in the response to infection in the lung. While some hormones, such as leptin, resistin and lipocalin-2 promote pro-inflammatory responses and immune cell infiltration, others including adiponectin and ghrelin reduce inflammation and promote anti-inflammatory cell responses. Furthermore, type 2 diabetes as a major endocrine disease presents with altered immune responses leading to susceptibility to lung infections, such as tuberculosis. A better understanding of these interactions will expand our knowledge of the mechanisms at play in susceptibility to infectious diseases and may reveal opportunities for the development of host-directed therapies.

Keywords: immuno-endocrine interactions, hormone, type 2 diabetes, tuberculosis, hormone receptor

INTRODUCTION

There is a growing interest in the relationship between the immune and endocrine systems (1). Bidirectional communication between the immune and endocrine systems facilitates optimal host responses during infection and homeostasis. This communication is possible since endocrine organs express cytokine receptors and cells of the immune system express hormone receptors (2). Metabolic,
nutritional, psychosocial, and genetic factors influence the immune response via endocrine signaling. During infection, cytokines produced by immune cells directly or indirectly alter hormonal responses, developing a feedback response between the endocrine and immune systems. Cytokines induce alterations in hormone production, by directly affecting endocrine organ function, such as IL-1, IL-6, and TNF-α. These cytokines increase the activity of the hypothalamus-pituitary-adrenal (HPA) and hypothalamus-pituitary-thyroidal (HPT) axes, and reduce that of the hypothalamus-pituitary-gonadal (HPG) axis (3–6), or indirectly by promoting cellular destruction of endocrine cells, as in the pancreatic dysfunction of type 2 diabetes (T2D) (7).

Hormones exert a profound effect on the functions of the immune system, exemplified by the anti-inflammatory functions of glucocorticoids (GCs) and androgens (8). While acute stress may be beneficial for the immune system during fight or flight, chronic stress is harmful. Chronic inflammation signal cortisol release through inflammatory signaling as well as the HPA axis and can drive HPA axis dysfunction if left unchecked. Stress-induced activation of the HPA axis results in the secretion of corticotropin releasing hormone (CRH) from the hypothalamus, which stimulates the production of adrenocorticotropic hormone (ACTH) from the anterior pituitary gland. ACTH stimulates the adrenal glands to produce cortisol, a potent anti-inflammatory hormone. To limit long-term exposure of tissues and cells to the immunosuppressive actions of cortisol, a negative feedback loop allows cortisol to regulate its own secretion. Long-term exposure to elevated levels of cortisol may lead to adaptations in HPA axis function, resulting in an initial increase in cortisol production (hypercortisolism) followed by a decrease in the production of the hormone (hypocortisolism) or cortisol resistance (9). Thus, chronic inflammatory responses and a dysregulated HPA axis result in altered cytokine signals and immune cell function (10).

Type 2 diabetes is a metabolic disease that presents with numerous alterations in hormone levels, including increased insulin and cortisol levels, and reduced free triiodothyronine (fT3) and testosterone levels (11–14) (Table 1). Common comorbidities of T2D include depression, asthma, and chronic obstructive pulmonary disease, which are co-prevalent and may indicate a relationship between stress-related hormonal alterations and lung function, as well as hypothyroidism (34). Altered endocrine responses in T2D are, in part, related to dysregulation of the HPA, HPT, and HPG axes, having downstream effects on immune functions within various organs (35–37).

Although the lungs are a major site of acquired infections, the effects of hormonal dysregulation on the immune response within the lung are still largely unknown. This review discusses hormones with immune modulatory potential in the lung and their influence on the immune response therein (summarized in Figure 1). Implications for susceptibility to tuberculosis (TB) are highlighted, drawing on examples of endocrine dysregulation in the form of T2D.

### CENTRAL ENDOCRINE (HYPOTHALAMIC AND PITUITARY) HORMONES

**Corticotropin Releasing Hormone (CRH)**

CRH is primarily produced by the hypothalamus, but can also be expressed at peripheral sites where it acts as an autocrine or paracrine inflammatory modulator (38, 39). CRH binds with a high affinity to CRH receptor 1 (CRHR1) and CRH-like peptides with a high affinity to CRHR2. CRHR2 is the major receptor expressed in human lungs, however compared to other tissues (heart, stomach, liver, and adrenal), the lung and skeletal muscle express the highest levels of CRHR1 (40). In mice, the CRHR1/
R2 ratio changes in response to stress in different immune cell types in the lung (41). CRHR1 mRNA increases and CRHR2 decreases in dendritic cells, whereas CRHR2 increases in macrophages in response to stress. Furthermore, CRHR2 is found to be preferentially expressed in neutrophils in the lungs of mice (42).

Differential expression of CRHR1 and CRHR2 in phagocytic cells in the lungs could affect innate cell function, potentially leading to altered adaptive immune responses. Limited information is available on how targeting CRH and CRHR activity in the respiratory tract impacts bacterial disease outcome. In a murine respiratory *Streptococcus pneumoniae* infection model, Burnley and Jones (2017) demonstrated that intranasal CRH administration reduces the pulmonary inflammatory response, and the subsequent recruitment of neutrophils and monocytes to the lung, improving survival in these animals (43). Moffat et al. (2006) demonstrated that, urocorcin, a structurally related peptide to CRH, causes bronchorelaxation and limits lipopolysaccharide (LPS)-induced pulmonary inflammation (specifically neutrophil recruitment) to a greater extent than CRH (44). During *S. pneumoniae* infection in the lungs of CD-1 mice, an outbred strain of albino mice, prior CRHR2 antagonist (astressin 2B) treatment reduces pulmonary bacterial growth and prevents sepsis, while CRHR1 antagonism (antalarmin) provided no benefit (39). Stimulation of CRHR in the lung, therefore, provides a promising approach for reducing excessive inflammation in the lungs and should be studied further.

### Adrenocorticotropic Hormone (ACTH)

ACTH is a pituitary hormone that signals via melanocortin receptors (MCRs), of which there are five. They are expressed on a wide range of tissues, including nervous, intestinal, adipose, skeletal, and lung tissues. Among these receptors, MC1R and MC5R are expressed in lung tissues. MC1R, MC3R, and MC5R are expressed on macrophages and lymphocytes, while MC2R and MC4R are expressed on lymphocytes (45). Cleavage of the first 13 amino acids of ACTH yields alpha melanocyte-stimulating hormone (α-MSH). ACTH and α-MSH exert broad anti-inflammatory effects in a variety of tissues by signaling through the MCRs, with the major receptor exerting these effects being MC1R (45). Additionally, numerous anti-inflammatory melanocortin-based therapies are in clinical trials for the treatment of inflammatory conditions (46). In allergic mice, intraperitoneal α-MSH reduced peribronchial airway inflammation, altering leukocyte populations in bronchoalveolar lavage (BAL) fluid, and reduced IL-6, TNF-α, and TGF-β gene expression; and leukocyte infiltration in the lung (48, 49). Thus, MCR stimulation in the lung may provide a novel target for its anti-inflammatory properties, providing repurposing potential for current agonists used to treat obesity (setmelanotide), porphyria (afamelanotide), and reduced sexual desire in women (bremelanotide) (50).

### Growth Hormone-Releasing Hormone (GHRH) and Growth Hormone (GH)

GHRH is secreted predominantly by the hypothalamus and stimulates the secretion of GH by the pituitary gland and regulates hepatic insulin-like growth factor-1 (IGF-1) production through the GH/hepatic IGF-1 axis (51).
tissues, including the lungs also produce GHRH locally and express the receptor of GHRH (GHRHR) as well as the GHRHR splice variant 1 (SV1) (52). In normal mouse lung tissue, type 2 cells, club cells and fibroblasts, lymphocytes, and dendritic cells express GHRH (52). GHRH is involved in lung homeostasis, inflammation and fibrosis (51). Antagonists for GHRHR have anti-inflammatory, pro-apoptotic, anti-oxidative and anti-fibrotic effects in the lung. The GHRH antagonist MIA-602, frequently used in bleomycin-induced lung fibrosis models, suppresses ERK/JAK2/STAT3 pathway activation and increases P53 and pAMK levels (53). At mRNA level MIA-602 downregulates pathways involved in adaptive immune responses including T cell activation and differentiation, T cell signaling and cytokine production (54). In a sarcoidosis granuloma model, GHRHR inhibition results in reduced IL-12 and IL-17A production (54, 55). Thus, MIA-602 demonstrates the contribution of GHRHR to adaptive immunity and T cell function, and that GHRHR is a potential candidate for managing these responses when they are excessive, such as in granulomatous diseases.

The ability of GHRHR signaling to modulate lung immune responses was further demonstrated in a study assessing the vaccine-induced immune responses of GHRH knockout mice against S. pneumoniae. Knock-out mice were significantly more susceptible to infection after vaccination than wild-type mice, with vast infiltration of neutrophils and monocytes, and reduced B cells and T cells in the lung post infection (56). These knock-out mice were unable to mount a pneumococcal vaccine-induced response, a deficiency restored by GH treatment, highlighting the importance of GH signaling in the lung immune response. The pro-inflammatory characteristics of GH have been demonstrated by exacerbating LPS-induced inflammation and cecal ligation and puncture (CLP)-induced sepsis by increasing neutrophil NF-kB activity, neutrophil presence, microvascular injury, and neutrophil CD11b expression in the lungs of rats (57, 58). In contrast, others have found GH treatment to prevent acute lung injury by reducing ICAM-1 expression and NF-kB activity in lungs (59, 60). The two studies displaying the pro-inflammatory effects of GH administered the GH subcutaneously to male Wistar rats, while the latter studies observing anti-inflammatory effects administered the GH intramuscularly in Sprague-Dawley rats and pathogen-free Kun Ming mice, respectively. Considering endocrine differences between Wistar and Sprague-Dawley rats (61), hormone-induced responses may differ and validation of observations across model organisms is key for avoiding model specific interpretations.

ADRENAL HORMONES

Glucocorticoids (GCs) and Mineralocorticoids

Cortisol is a known immune modulator and synthetic GCs have been used clinically to control inflammatory conditions, such as asthma, for decades. Cortisol is produced from cholesterol that is converted to pregnenolone before the steroidogenic pathway diverges toward the formation of this major class of steroid hormones. It signals via the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR), which are ubiquitously expressed, including in the lung (62).

High doses of GCs reduce the number of macrophages in the respiratory tract and impair the functional activity of resident lung macrophages (63). GCs are produced in T-cells and macrophages of the lung upon stimulation with inflammatory mediators, including TNF-α, LPS, and anti-CD3, acting as an immunoregulatory mechanism to limit uncontrolled inflammatory responses in the lung. This GC stimulatory effect was promoted by intranasal leptin pretreatment in mice with LPS-induced acute lung injury (64, 65). More recently Marin-Luevano et al. (2021) demonstrated that cortisol promotes the intracellular growth of Mycobacterium tuberculosis in A549 type 2 pneumocytes and THP-1-derived macrophages, but not airway bronchial epithelial cells (66), highlighting the immunosuppressive effects of GCs in the lung. Long-term (>1 year) treatment with inhaled corticosteroids is implicated in increased risk of developing pneumonia (risk ratio of 1.41) and is associated with the risk of mycobacterial diseases, such as TB (67).

Androgens

Dehydroepiandrosterone (DHEA) is produced from cholesterol, predominantly in the zona reticularis of the adrenal glands upon ACTH stimulation, and in the gonads upon luteinizing hormone and follicle-stimulating hormone stimulation. Receptors for DHEA include the androgen receptor (AR), estrogen receptor (ER), peroxisome proliferator activated receptor-alpha (PPARα), pregnane X receptor, and neurotransmitter receptors, such as the N-methyl-D-aspartate (NMDA) receptor (68, 69).

DHEA treatment is associated with reduced pulmonary hypertension by upregulating soluble guanylate cyclase and by inhibiting src/STAT3 pathway activation, a key pathway in cytokine-induced cell activation and proliferation (70, 71). Generally DHEA counteracts the effect of cortisol, and more specifically in alveolar macrophages, restores the expression of the receptor for activated C kinase (RACK-1) and LPS-induced TNF-α and IL-8 production that is reduced due to aging in rats (72). When added to alveolar macrophages from non-smoking asbestos workers in vitro, DHEA reduces the release of superoxide anion (73), which is consistent with its role in limiting Th2 responses (74). Intratracheal administration of 16α-bromoepiandrosterone (BEA; a DHEA-related synthetic sterol) reduces the bacterial load and inflammation in the lungs of diabetic mice who are infected with M. tuberculosis (75). BEA decreases the expression of the enzyme 11β-hydroxysteroid dehydrogenase type 1, which catalyzes the conversion of inactive cortisol into active cortisol in humans and inactive dehydrocorticosterone into active corticosterone in mice. At the same time, it increases the expression of 11β-hydroxysteroid dehydrogenase type 2, which again converts active cortisol/corticosterone into inactive cortisone/dehydrocorticosterone. This could increase IFN-γ and TNF-α response resulting in lower bacterial loads in the lungs of these animals. The ability of DHEA and BEA to improve immune and
metabolic (as shown in the TB-T2D mouse model) responses suggests that they could potentially be used as therapeutic agents, which will benefit the host’s immune, endocrine and metabolic functions.

**THYROID HORMONES: THYROXINE (T4) AND TRIIODOTHYRONINE (T3)**

The lungs express lower levels of the thyroid hormone receptors THRA1, THRA2, and THRBI mRNA than other tissues, however the relative protein expression of THRA2 and THRBI in lung tissue is higher than in other human tissues (76). Furthermore, THRA expression in the lung is highest in alveolar type 1 epithelial cells, while their expression is similar in lung T cells, granulocytes, type 2 alveolar cells, and macrophages. THR on the other hand is expressed predominantly in type 2 alveolar cells (77). In rats, thyroid hormone receptors were also found in lung type 2 alveolar cells, and promote GC responses and adenylyl cyclase activity in the lung (78–80). Additionally, T3 activates the MAPK/ERK1/2 pathway in rat alveolar epithelial cells and increases their sodium-potassium-ATPase pump content and activity (81).

More recently, Ning et al. (2018) described the ability of T4 to reduce the inflammatory response and senescence in an oxidized low-density lipoprotein-induced foamy macrophage model (82). In a type 2 deiodinase-knockout mouse model, active thyroid hormones are not produced in the thyroid gland. Type 2 deiodinase-knockout mice have a greater susceptibility to ventilator-induced lung injury, with increased Cxcl2, Tnf, Il1b, and Cxcl2 gene expression. Treatment with T3 ameliorated the higher cytokine and chemokine expression in knockout mice (83). Although it remains unclear whether these effects were mediated by the THR, this highlights the anti-inflammatory effects of T3 and potentiates a relevance for T3 signaling in the lung. Studies assessing the influence of thyroid hormones on lung function during infection would provide valuable information against infections.

**GONADAL HORMONES**

**Testosterone**

Differences between male and female responses in disease are common, highlighting a potential role for sex hormones in disease. Testosterone acts via the AR, which is expressed in human lungs primarily in endothelial cells and club cells, fibroblasts, and type 2 alveolar cells, with lower expression in macrophages, T cells, and granulocytes (84). Testosterone exposure in mouse lungs upregulates genes involved in iron binding and oxygen transport while downregulating genes involved in DNA repair and recombination (85). In an asthma mouse model, ovalbumin sensitized male mice displayed lower susceptibility to inflammation due to lower Th2 cytokine production and lung lymphocyte levels compared to female mice (86). Becerra-Diaz et al. (2018) investigated the immune modulatory functions of AR signaling in the lungs, and found that dihydrotestosterone reconstitution in castrated mice reduced lung inflammation and enhanced M2 polarization of alveolar macrophages via IL-4 stimulation (87). Similarly, gonadectomized male mice infected with influenza A virus and treated orally with testosterone have reduced pulmonary monocyte and virus-specific CD8+ T cell infiltration resulting in improved disease outcomes (88). Testosterone decreases pro-inflammatory cytokine release from monocytes and macrophages, and increases the accumulation of cholesterol esters in human monocyte-derived macrophages (89). Additionally, type 2 innate lymphoid cells express AR, the signaling of which inhibits their maturation and IL-33-mediated lung inflammation.

**Estrogen**

Estrogens comprise three major forms, estrone, estradiol, and estriol. Their proportions fluctuate depending on the processes occurring in the body, with estradiol predominating most of the time. During pregnancy, enzymes in the placenta transform 16α-hydroxy-dehydroepiandrosterone sulfate (16α-OH-DHEAS) to estriol. Estrone is produced mostly during menopause. Signaling of these hormones is mediated by the α and β forms of the ER. Both ER forms are expressed in human and mouse lungs, and human lung cell lines; although in humans, ER-α presence varies among individuals (90). ER-α predominates in lung fibroblasts, with low expression in endothelial cells, granulocytes and macrophages, while ER-β predominates in human lung alveolar type 1 cells, ciliated cells, and granulocytes (84). Histological analysis in CD-1® IGS mouse and porcine lung show no ERα expression (91, 92), while RT-PCR in BALB/c mice shows expression of both receptors in the lung, with lower ERα expression (93). Kan et al. (2008) investigated the effect of 17β-estradiol (E2) on trauma-hemorrhage-induced lung injury in Sprague-Dawley rats. E2 administration induced higher endothelial nitric oxide synthase (eNOS) expression and phosphorylation, protein kinase G-1 activation, and VASP expression, resulting in reduced lung injury (94). These anti-inflammatory properties were also demonstrated in seawater induced acute lung injury in rats, which was reduced by E2 treatment (95). Despite ERβ predominance, ER-α is reported to be responsible for the anti-inflammatory effects of ER stimulation (96).

**HORMONES OF THE GASTRO-INTESTINAL TRACT**

**Gastric Inhibitory Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1)**

The GIP receptor (GIPR) is present in airway ciliated and club cells, alveolar pneumocytes and lung macrophages (77). In atherosclerosis mouse models, GIP has been shown to prevent monocyte and macrophage activation (97, 98). Studies into the immune regulatory roles of GIP are scarce and may reveal additional functions of this hormone on the lung immune response.
The GLP-1 receptor (GLP-1R) is expressed in the lungs of mice and humans at a higher level than other tissues (99, 100). Numerous studies, as reviewed by Lee and Jun (2016), describe the anti-inflammatory effects of GLP-1 and the potential of GLP-1-based therapies (101). In a BALB/c mouse model of ovalbumin-induced asthma, protein kinase A (PKA) phosphorylation was inhibited and NF-κB p65 upregulated in the lung. GLP-1 agonist treatment in these mice led to PKA activation and downstream inhibition of NF-κB, mediating anti-inflammatory responses in the lung by reducing the infiltration of inflammatory cells, tissue pathology, Th2-associated cytokines in BAL fluid, and E-selectin expression (102). Gou et al. (2014) showed that bleomycin-induced pulmonary fibrosis in mice presents with an increase in macrophages and lymphocytes, as well as TGF-β1 concentrations in the BAL fluid, and VCAM-1 expression and NF-κB activation in the lung. GLP-1 agonist liraglutide, when administered intraperitoneally, reduces these characteristics of bleomycin-induced lung inflammation and fibrosis (103). Although subcutaneous liraglutide improved lung function in a chronic obstructive pulmonary disease mouse model, this effect was not accompanied by a reduction in lung inflammation. Additionally, liraglutide did not alter inflammatory cytokine responses in another study by the same group (100, 104). These differences in observations suggest that intraperitoneal administration may be required to produce the anti-inflammatory effects of GLP-1 in the lung. Other possible immunomodulatory mechanisms of GLP-1 may involve alteration of T cell function by reducing CD28 and CD86 expression, and reducing tissue factor and PAI-1 production (105). While GIPR function in the lung immune response requires further investigation, GLP-1R may reduce inflammation by mediating immune cell recruitment and activation in the lung, although it is not crucial for a balance between pro- and anti-inflammatory responses.

Ghrelin
Since its discovery in 1999, numerous actions of ghrelin have been described ranging from metabolic homeostasis, circadian rhythms, learning and memory to immune modulation. Ghrelin binds to the growth-hormone secretagogue receptor 1a (GHSR-1a), inducing GH release from anterior pituitary cells in a process having the highest ghrelin expression in Wistar rats (109). In two studies assessing human lungs, mRNA and protein expression of ghrelin and biologically inactive GHSR-1b was detectable, while those of GHSR-1a were not (110–112).

Despite this, ghrelin treatment is associated with alterations in inflammatory responses in lung tissues, including a reduction in inflammatory cytokine release, NF-κB pathway activation, neutrophil infiltration, and improved survival in rats with CLP-induced lung injury (113). Additionally, these anti-inflammatory effects may be related to the acetylation status of ghrelin, since only acyl ghrelin and not des-acyl ghrelin binds to GHSR-1a (114). Interestingly, it has been proposed that GHSR-1a is not required for the anti-inflammatory actions of ghrelin, suggesting another as yet unknown signaling mechanism mediating these effects (115). LPS-induced apoptosis of alveolar macrophages is attenuated by ghrelin, with GHSR-1a–mediated JNK inhibition and Wnt/B-catenin activation, promoting alveolar macrophage survival and their anti-inflammatory responses. In GHSR-1a knockdown mediated by siRNA, these effects were abrogated, highlighting the need for GHSR-1a signaling in these anti-inflammatory and anti-apoptotic responses (116). In a CLP-induced Sprague Dawley rat sepsis model, ghrelin treatment improved survival and reduced peritoneal bacterial load and pulmonary TNF-α and IL-6. Signaling via the GHSR-1a receptor was responsible for improving mortality. Additionally, the CLP-treated group without ghrelin administration had significantly lower ghrelin content in the lung (117). A more recent study also noted that in the lung with elastase-induced emphysema, ghrelin polarized alveolar macrophages to the M2 phenotype, decreased keratinocyte-derived chemokine (a mouse IL-8 analogue), TGF-β, and TNF-α, increased IL-10 levels, and promoted lung tissue recovery in C57BL/6 mice (118). Exogenous administration of ghrelin reduced pulmonary hypertension in a monocrotaline-induced mouse model (119). Ghrelin may play a key role in altering the immune response, possibly linking gastro-intestinal tract function and metabolism to immunity in the lung. Further, studying the effects of ghrelin receptor agonists on the lung may provide an important avenue for host-directed therapy during lung infection and inflammatory conditions.

**PANCREATIC HORMONES**

**C-Peptide**
C-peptide is a 31 amino acid peptide that links the insulin A and B subunits and is cleaved from proinsulin to form insulin. Despite evidence of C-peptide–induced intracellular signaling activity in KATOII cells (a human gastric tumor cell line), a specific receptor for C-peptide has been elusive and a proposed receptor, GPR146, remains contentious (120, 121). However, its chemotactic properties were noted when in vitro experiments showed that C-peptide increases human monocyte chemotaxis in a concentration-dependent manner (122). Several studies identified beneficial effects of C-peptide in the lungs. C-peptide treatment ameliorates the inflammatory response and lung inflammation resulting from hemorrhagic shock in male Wistar rats, reducing plasma IL-1, IL-6, MIP-1α, and CXCL1 (123). Jeon et al. (2019) found that C-peptide prevents vascular leakage by inhibiting VEGF-induced transglutaminase 2 activation in the lungs of streptozotocin-treated mice and human pulmonary microvascular endothelial cells (124). These findings were also corroborated in C57BL/6 mice treated with C-peptide after hemorrhagic shock and resuscitation, showing a reduction in inflammatory markers and pulmonary protein leakage (125). Furthermore, Vish et al. (2007) used a Swiss albino mouse model with LPS-induced endotoxic shock to investigate the effects of C-peptide treatment. LPS treatment in the lungs of mice reduced PPARγ gene expression, stimulated ERK1/2 activation, and induced lung injury. These effects were

---

*Webber et al.* Immuno-Endocrine Responses in the Lung
reversed by C-peptide treatment (126). While PPARγ has been shown to have anti-inflammatory effects, ERK1/2 activation is involved in developing a pro-inflammatory response. These findings indicate an anti-inflammatory nature of C-peptide signaling in the lung, though further studies in this field are required to determine insights in its pulmonary effects and influence during infection. The identification and characterization of the signaling mechanisms of C-peptide are key to understanding its effects and potential applications.

**Insulin**

The insulin receptor (IR) is expressed in varying degrees across diverse tissues, including the lungs. In the lungs, IR gene expression predominates in endothelial cells, club cells and ciliated cells, and alveolar type 1 and type 2 cells, with lower expression in lung immune cells (84). The two IR isoforms, IR-A and IR-B, and IGF-1R bind their ligands, insulin, proinsulin, IGF-1, and IGF-2, with differing potencies (EC_{50}). IR-A displays the lowest EC_{50} values for insulin, proinsulin, and IGF-2 (127). IR-B predominates in the liver and adipose tissue, while leukocytes only express the IR-A isoform (128). Different pathways are activated by the two IR isoforms (129) indicating that an altered ratio of the isoforms can alter the outcomes of insulin signaling.

GC treatment increases IR expression, while hypothyroidism induction reduces the IR expression in fetal rabbit lung, indicating the influence of other hormones on the lung’s insulin response (130). During allergic lung inflammation in rats, insulin secretion and IR expression is increased on infiltrating inflammatory cells, predominantly monocytes and macrophages (131). In an elastase-induced emphysema Wistar rat model with alloxan-induced diabetes, diabetic rats had significantly lower leukocyte infiltration into the lungs, which was significantly increased upon subcutaneous treatment with insulin (132). While suggesting that insulin treatment improves the deficient immune cell migration in diabetes, it also may indicate pro-inflammatory effects due to leukocyte recruitment, although this study did not use a vehicle treatment control to compare with the insulin treated group.

Martins et al. (2008) isolated alveolar macrophages by BAL from male Wistar rats and stimulated them with LPS to assess the inflammatory response. In the insulin treated cells after LPS-stimulation, there was a significant reduction in the LPS-induced p38 MAPK, PKC, and Akt activation, and TNF-α secretion (133). A similar study in specific-pathogen-free C57BL/6 mice with alloxan induced diabetes found that insulin treatment of alveolar macrophages decreased LPS-induced TNF-α and IL-6 production ex vivo (134). Thus, the response of the lung tissue to insulin is still unclear, although some studies indicate anti-inflammatory changes in gene and cytokine expression in alveolar macrophages treated with insulin, others suggest that insulin treatment promotes leukocyte migration to the lung. There is however limited information available regarding the effects of insulin resistance and hyperinsulinemia on immune function in the lung, despite numerous studies on respiratory function in these cases. Understanding these lung responses to insulin is crucial in the application of insulin treatments, including inhalants and injectables, and understanding the pathogenesis of infection in the lungs of patients with diabetes mellitus.

**Glucagon**

Reports of glucagon receptor (GCGR) expression and function in the lung are scarce. While two studies suggest little to no expression of GCGR in the lungs of rats, another study suggests its predominant expression in mouse lungs, liver, kidney, adrenal glands, and stomach (135–137). Glucagon receptors have been identified in lymphocytic cells from mice and rats, and in lymphoid cell lines (138).

Nebulized glucagon delivery to the lung improves the forced expiratory volume by 22% in asthmatic patients with methacholine-induced bronchospasm (139). This indicates responsiveness of the lung smooth muscle to glucagon. It was later shown that glucagon induces smooth muscle relaxation in the lungs of male A/J mice by inducing cAMP response element binding protein (CREB), eNOS, and cyclooxygenase 1 (COX-1) activity, and the subsequent release of second messengers nitric oxide and prostaglandin E2 (140). In this study, glucagon treatment one hour before LPS administration limited LPS-induced lung inflammation and airway hyperreactivity, preventing increases in TNF-α levels. Unlike neutrophils, LPS-induced monocyte infiltration was not reduced by glucagon pretreatment, indicating that glucagon may not influence monocyte migration and chemotaxis. This group further assessed the anti-inflammatory properties of glucagon in ovalbumin-induced lung inflammation and airway hyperreactivity (141). Glucagon treatment prevented airway hyperreactivity and eosinophilia, and reduced IL-4, IL-5, IL-13, TNF-α, CCL11, and CCL24 levels in lung tissue.

**ADIPOSE HORMONES**

**Adiponectin**

As summarized in Ye et al. (2013), adiponectin affects metabolic functions, such as glucose metabolism, insulin sensitivity, oxidative stress, and inflammation, in numerous systems, including adipose tissue, B cells, and macrophages (142). The miRNA expression of adiponectin receptors AdipoR1 and AdipoR2 have been demonstrated by Northern blot in mouse and human lung tissues, although a considerably lower expression was observed in human lung tissue compared to other tissues (143). Constant adiponectin infusion (using osmotic pumps) in BALB/cj mice reduces allergic airway inflammation and hyperresponsiveness induced by ovalbumin challenge, while the lack of adiponectin in knockout mice promotes greater allergic airway inflammation (144). Additionally, adiponectin knockout mice have a higher frequency of TNF-α producing alveolar macrophages, which is reduced upon adiponectin supplementation, and increased transcription of IL-1α, IL-6, IL-12β, IL-17, and TNF-α in their lungs during aspergillosis, than wild type mice (145).

In humans, several studies report an inverse association of serum adiponectin and asthma prevalence and severity (146).
Adiponectin promotes an anti-inflammatory M2 macrophage phenotype, while inhibiting an M1 phenotype. This was observed when adiponectin deficient mice displayed a predominance of M1-polarized macrophages and fewer M2-polarized macrophages in the peritoneum and adipose tissue. Treatment with adiponectin reversed this observation, promoting an M2 phenotype in human monocyte-derived macrophages and adipose tissue cells, and reducing LPS-stimulated TNF-α, iNOS, and MCP-1 gene expression (147). Agonist therapy of the adiponectin receptor shows promise against inflammatory conditions such as systemic sclerosis, obesity-related disorders, and T2D. This was shown using the adiponectin agonist, AdipoRon, which ameliorated signs of diabetes in db/db and high fat diet fed mice, and ameliorated dermal fibrosis in mice, also promoting a Th2/Th17 immune response (148, 149). While adiponectin is an abundant adipokine and displays anti-inflammatory functions, more information is needed on whether its levels are altered to compensate for inflammation. Additionally, the applications of adiponectin agonist therapy against lung inflammatory responses require further investigation.

Leptin

Leptin regulates innate and adaptive functions of immune cells. Leptin upregulates phagocytosis and pro-inflammatory cytokine production via phospholipase activation, and stimulates lineage marker expression, including HLA-DR, CD11b, and CD11c in monocytes (150). Thus, leptin is an important pro-inflammatory mediator predominantly produced in adipose tissue. Leptin receptor mRNA, including OB-Ra, -Rb, and -Re subtypes, are expressed in the mouse lung (151, 152).

Leptin receptor deficient db/db mice infected with M. tuberculosis have a higher lung bacterial load, disorganized granulomas, and abnormalities in lung cytokine production, with delayed IFN-γ production as compared to wild-type mice (153). Similarly, leptin deficient ob/ob mice with pulmonary infection by Klebsiella pneumoniae, S. pneumoniae, or M. abscessus have reduced survival (154). Suzukawa et al. (2015) used bronchial cells in ex vivo cultures to assess the effects of leptin stimulation on lung cells, notably these specimens were obtained from lung with localized tumors. Leptin treatment increased CCL11, G-CSF, VEGF, and IL-6 production and upregulated ICAM-1 expression, a change that coincided with activation of NF-kB, highlighting the pro-inflammatory potential of leptin and its ability to induce migration and chemotaxis of immune cells (155). This has implications for increasing the inflammatory response and leukocyte infiltration into the lung in individuals with increased leptin levels, such as during obesity. Additionally, OB-R expression was upregulated by IFN-γ and IL-1β, implying that during type 1 inflammatory responses, the lung epithelial cells are more sensitive to these pro-inflammatory effects of leptin. These effects were recapitulated in later work by the same group in a lung fibroblast cell line (156).

Thus, although leptin presence may be required for a functional immune response to infection, higher levels may promote excessive inflammation. These effects require further investigation given the importance of increased leptin during obesity and T2D, which display higher prevalence of comorbid lung diseases (157).

Lipocalin-2

Lipocalin-2, or neutrophil gelatinase associated lipocalin (NGAL), is an adipokine with broad tissue expression. Zhang et al. (2012) investigated this using tissue microarray technology across humans tissues from embryos, fetuses, neonates, and adults (158). This study demonstrated expression of NGAL and its receptor (NGALR) in nervous, renal, adrenal, pituitary, spleen, lymph node, and skin tissues, with NGALR additionally expressed in lung and pancreatic tissues in adults.

NGAL influences the immune response by polarizing macrophages to an M1 phenotype (159), and altering neutrophil chemotaxis and cytokine secretion (160). Wang et al. (2019) investigated these immune modulating capabilities of NGAL, finding defective neutrophil chemotaxis, and reduced inflammatory cytokine and chemokine production in neutrophils and macrophages in NGAL deficient mice infected with E. coli, and increased macrophage migration and phagocytosis upon in vitro NGAL treatment (161). These findings were recapitulated in pulmonary M. tuberculosis infection in mice, whereby NGAL promoted neutrophil recruitment and alveolar macrophage G-CSF and CXCL1 production, while reducing T cell recruitment and CXCL9 production. NGAL deficiency resulted in larger granuloma size in chronic M. tuberculosis infection, coinciding with elevated lung T cell and CXCL9 presence (162). Furthermore, NGAL is important in the lung mucosal immunity against K. pneumoniae infection, playing a role in bacterial clearance (163). This study showed that NGAL is expressed on human bronchial epithelial cells in response to in vitro stimulation with IL-1β, IL-17A, IL-17F, or TNF-α, and in vivo upon K. pneumoniae infection in the lungs of C57BL/6 mice in a TLR4-dependent manner via the MyD88 signaling pathway. TLR4 knockout and NGAL knockout mice had significantly higher lung bacterial loads at 12 hours post infection, which was reduced significantly by exogenous NGAL administration 4 hours prior to sacrifice. Expression of NGAL is critical to the immune response in the lung and demonstrates essential functions during infection.

Resistin

Resistin is an adipokine that binds to TLR4 and channel-activating protease 1 (CAP1), a serine protease. Two studies demonstrated resistin binding to TLR4, with resistin activating TLR4 in porcine alveolar macrophages and competing with LPS for TLR4 in human monocytes (164, 165). TLR4 and CAP1 are expressed on human alveolar macrophages and type 2 alveolar cells, indicating that resistin could play a role in the lung immune response during infection (77, 166). Resistin binds to decorin and ROR1 in mice with a lower affinity, though these are rarely expressed on human monocytes and macrophages (167). ROR1 is expressed on human alveolar type 1 cells and decorin is expressed on human lung fibroblasts and endothelial cells.

Using a humanized mouse model, Jiang et al. (2014) demonstrated that resistin expression exacerbated LPS-induced lung injury via neutrophil recruitment to the lung during LPS
treatment and promoted their activation in the lung, with increased TNF-α and MIP-2 release, and increased neutrophil extracellular trap formation (168). Additionally, resistin-like molecules (RELMs) are homologues of resistin and have immunomodulatory effects, demonstrated in lung tissue, with pro-inflammatory and tissue remodeling capabilities (169, 170). Inflammation-mediated lung injury can occur via activation of TLR4/NF-κB pathways (171, 172). However, further studies are necessary to assess the effects of resistin signaling on lung immune function during infection.

**TYPE 2 DIABETES IMPACTS LUNG IMMUNE-ENDOCRINE INTERACTIONS: IMPLICATIONS FOR TB**

Endocrine alterations play a crucial role in the development and progression of T2D. Alterations in hormone levels have been identified in the plasma of T2D patients, implicating endocrine signaling in the dysregulation of inflammatory responses in T2D patients (173). Hormones with suggested pro-inflammatory properties in the lung are increased in the blood of T2D patients, such as TSH, leptin, resistin, and insulin (Table 1). Conversely, many hormones with potential anti-inflammatory effects are reduced during T2D, such as CRH, DHEA, T4, testosterone, adiponectin, NGAL, GIP, GLP-1, and ghrelin, while ACTH, cortisol, glucagon, and C-peptide also have anti-inflammatory potential but are raised in T2D patient blood plasma. This shift toward pro-inflammatory hormone signaling in T2D may be a mechanism for the low-grade chronic inflammation in T2D patients and provides an impetus for investigating immune-endocrine alterations in the lungs of these patients. It also indicates that a complex interaction between these hormones and the immune system is at play, requiring deconvolution before useful and exploitable insights can be gained.

Under the influence of diet and GIT function, gastric hormones contribute to the control of systemic inflammatory responses. Although GIP may play a role in compensating for insulin resistance, lower GLP-1 and ghrelin may indicate a predominance of inflammatory molecules and downregulation of anti-inflammatory mechanisms. Additionally, a role for the gut microbiome in influencing the immune response via gastric hormones lays an intriguing path for further research into T2D immune responses.

Foamy macrophage formation, which provides a niche for mycobacterial survival and supply crucial lipid nutrients to the bacilli, is suppressed by GIP and GLP-1 (174). During T2D, GLP-1 and GIP are reduced and dyslipidemia typically presents with higher levels of triglycerides (175), which accumulate in foam macrophages (176).

TB is a leading cause of death worldwide, with an incidence of 10 million and a mortality between 1.1 and 1.3 million in 2019 (177). T2D is a highly prevalent risk factor for increased disease severity, poor treatment outcomes, relapse, and death in TB patients, and is projected to rise from an estimated 9.3% in 2019 to 10.9% by 2045 (178). Pleural fluid of TB patients contains elevated levels of GH and cortisol compared to healthy controls (18, 179), while DHEA concentration is reportedly lower in the plasma of TB patients compared to that of healthy controls (3, 18).

Hormone levels change differently over the course of TB treatment between treatment failure and cured patients. These include cortisol, T4, and total amylin levels, which are higher in treatment failure compared to cured patients at month 6 of TB treatment, and decrease over the course of treatment in the cured patients only (1). These hormones may promote immunosuppression during treatment, reducing the function of immune cells to work synergistically with antibiotics to clear mycobacteria from the lung.

Santucci et al. (2011) and Fernandez et al. (2020) found lower leptin levels and higher cortisol levels in TB patients compared to controls, coinciding with higher inflammatory biomarkers, such as CRP, IL-6, and IL-1β (16, 31). Furthermore, Santucci et al. (2011) found leptin and cortisol changes to be more extreme in severe TB disease than in mild disease. OB gene knockout experiments in mice show that leptin is necessary for mycobacterial control and IFN-γ response (180). Characterising the effects of hormones on lung homeostasis and immune responses to infection is paramount. Experiments including overexpression and knockout of hormones and their receptor may highlight such effects.

The immune response to infection, such as during TB, involves recognition and phagocytosis of pathogens by macrophages and dendritic cells, killing by phagolyosome fusion, and presentation on major histocompatibility complexes allowing the activation of adaptive immune responses (181–183). However, T2D alters the immune response to *M. tuberculosis*, having reduced pathogen recognition, phagocytosis, killing, and presentation due to reduced pattern recognition receptor and major histocompatibility complex expression on macrophages. Altered macrophage lipid trafficking results in the formation of foam cells, with reduced phagocytic function and increased apoptosis, a cholesterol rich environment develops, providing nutrients to persisting mycobacteria. Lymphocytes dictate the developing immune response and altered lymphocyte levels in T2D include higher anti-inflammatory responses (Th2 and Treg) and reduced pathogen specific memory Th17 and Th1 responses, additionally natural killer cells are increased but their responses are reduced (184–186). The influence of hormones in determining these altered immune responses requires further investigation and their alteration during T2D provides a useful model for these altered immune responses (Figure 2).

Clinically, T2D delays TB treatment response, while also increasing the risk of poor TB treatment outcomes, relapse, and death (187–189). In addition, more severe presentations of TB are seen in T2D patients (190). Comorbid T2D alters TB and latent TB infection adipokine levels, with the pro-inflammatory adipokine leptin levels increased, while anti-inflammatory adiponectin levels decreased compared to those of TB patients without T2D (23), Kumar et al. (2016) found this change to be independent of BMI (23, 31). However, others have found opposite results, for example, Zheng et al. (2013) found higher leptin levels in TB patients and lower levels in TB-T2D patients.

---

**Table 1:**

| Hormone | T2D Plasma Levels |
|---------|------------------|
| CRH     | Reduced          |
| DHEA    | Increased        |
| T4      | Increased        |
| Testosterone | Decreased   |
| Adiponectin | Reduced   |
| NGAL    | Increased        |
| GIP     | Reduced          |
| GLP-1   | Reduced          |
| Ghrelin | Reduced          |
| ACTH    | Reduced          |
| Cortisol| Increased        |
| Glucagon| Increased        |
| C-peptide| Increased      |

---

**Figure 2:**

The immune response to infection, such as during TB, involves recognition and phagocytosis of pathogens by macrophages and dendritic cells, killing by phagolyosome fusion, and presentation on major histocompatibility complexes allowing the activation of adaptive immune responses (181–183). However, T2D alters the immune response to *M. tuberculosis*, having reduced pathogen recognition, phagocytosis, killing, and presentation due to reduced pattern recognition receptor and major histocompatibility complex expression on macrophages. Altered macrophage lipid trafficking results in the formation of foam cells, with reduced phagocytic function and increased apoptosis, a cholesterol rich environment develops, providing nutrients to persisting mycobacteria. Lymphocytes dictate the developing immune response and altered lymphocyte levels in T2D include higher anti-inflammatory responses (Th2 and Treg) and reduced pathogen specific memory Th17 and Th1 responses, additionally natural killer cells are increased but their responses are reduced (184–186). The influence of hormones in determining these altered immune responses requires further investigation and their alteration during T2D provides a useful model for these altered immune responses.
This result is unexpected, since wasting during TB disease is usually accompanied by decreased adiposity and leptin levels (26). This study also found lower ghrelin levels in TB patients with and without T2D. These disparities may be due to different genetic and socio-economic backgrounds within the study populations. Clarity regarding these hormones may require larger studies in participants from diverse genetic backgrounds.

**DISCUSSION**

Endocrine alterations contribute to changes in immune responses. While some hormones have been studied extensively for their immune-regulatory properties, few have been sufficiently investigated in the lung immune response to infection and compared to their effects outside the lung. Fewer still have been assessed in the lungs during T2D, a major endocrine dysregulating disease, and TB, a bacterial lung disease. While we have discussed more defined hormones in this review, others including progesterone, thyroid-stimulating hormone, parathyroid hormone, epinephrine, norepinephrine, melatonin, adipsin, require further investigation. Additionally, while some evidence suggests that receptors for hormones are not expressed in the lung tissue, such as C-peptide and ghrelin, other studies have described responses of lung tissue or immune cells to these hormones, indicating that alternative pathways of stimulation may be responsible for these effects or more sensitive methods are required for their evaluation in lung tissue.

Elucidating the role of these hormones in modulating immune cell function in the lung will bridge a critical gap in our understanding of immune responses in the lungs.

Many studies thus far have investigated hormone-induced cellular responses in cell lines, peripheral blood cells, and in mouse and rat models. Cells under specific environmental conditions respond to hormonal stimulation differently. Thus, interpretation of these studies must be considered according to the cellular compartment or animal model they were performed in. While providing informative results, the relevance of these results to disease in the human lung remains to be validated with studies based on the human lung. Future studies assessing endocrine driven immune responses in the lung should incorporate human tissues or cells, like lung biopsies or resections and BALF, to build on current knowledge in this field with more relevance to human disease.

Understanding the factors contributing to the development, progression, and treatment response of lung diseases is crucial for improving the avenues of treatment, such as host-directed therapies, especially since antibiotics in development are deemed a short-term solution needing supplementation by other means of treatment (191). Hormone receptors may provide improved...
adjunctive therapeutic targets, given an improvement in our understanding of their functions in the lung under disease.

AUTHOR CONTRIBUTIONS

TW and LK conceived the idea for the review. TW, LK, and KR reviewed the current literature. TW and LK wrote the manuscript. TW, LK, MCS, and KR critically reviewed the manuscript.

REFERENCES

1. Kleynhans L, Ruzive S, Ehlers L, Thiart L, Chegou NN, Conradie M, et al. Changes in Host Immune-Endocrine Relationships During Tuberculosis Treatment in Patients With Cured and Failed Treatment Outcomes. Front Immunol (2017) 8:690. doi: 10.3389/fimmu.2017.00690
2. Csaba G. Hormones in the Immune System and Their Possible Role. A Critical Review. Acta Microbiol Immunol Hung (2014) 61:241–60. doi: 10.1556/AMicr.61.2014.3.1
3. Del Rey A, Mahuad CV, Bozza VV, Bogue C, Farroni MA, Bay ML, et al. Endocrine and Cytokine Responses in Humans With Pulmonary Tuberculosis. Brain Behav Immun (2007) 21:171–9. doi: 10.1016/j.bbi.2006.06.005
4. Besedovsky HO, del Rey A, Kluwe B, Bozza V, Bogue C, Farroni MA, et al. Adrenocorticotropin-Releasing Hormone (CRH) Levels in Patients With Non-Inspuln Dependent Diabetes Mellitus (NIDDM). Endocr (1993) 40:705–9. doi: 10.1007/en/10705
5. Santucci N, D’Attilio L, Kovalevsky I, Bozza V, Besedovsky H, del Rey A, et al. A Multifaceted Analysis of Immune-Endocrine-Metabolic Alterations in Patients With Pulmonary Tuberculosis. PLoS One (2011) 6:e26363. doi: 10.1371/journal.pone.0026363
6. Cho JH, Kim HJ, Lee JH, Park IK, Moon JS, Yoon JS, et al. Poor Glycemic Control Is Associated With the Risk of Subclinical Hypothyroidism in Patients With Type 2 Diabetes Mellitus. Korean J Intern Med (2016) 31:703–11. doi: 10.3904/kjim.2015.198
7. Hashimoto K, Nishioka T, Takao T, Numata Y. Low Plasma Corticotropin-Releasing Hormone (CRH) Levels in Patients With Non-Inspuln Dependent Diabetes Mellitus (NIDDM). Endocr (1993) 40:705–9. doi: 10.1007/en/10705
8. Santucci N, D’Attilio L, Kovalevsky I, Bozza V, Besedovsky H, del Rey A, et al. A Multifaceted Analysis of Immune-Endocrine-Metabolic Alterations in Patients With Pulmonary Tuberculosis. PLoS One (2011) 6:e26363. doi: 10.1371/journal.pone.0026363
9. Cho JH, Kim HJ, Lee JH, Park IK, Moon JS, Yoon JS, et al. Poor Glycemic Control Is Associated With the Risk of Subclinical Hypothyroidism in Patients With Type 2 Diabetes Mellitus. Korean J Intern Med (2016) 31:703–11. doi: 10.3904/kjim.2015.198
10. Fernández R, Díaz A, D’Attilio L, Bongiovanni B, Santucci N, Bertola D, et al. An Adverse Immune-Endocrine Profile in Patients With Tuberculosis and Type 2 Diabetes. Tuberculosis (2016) 101:95–101. doi: 10.1016/j.tube.2016.09.001
11. Al Hayek AA, Khader YS, Jalal S, Khawaja N, Robert AA, Ajlouni K. Prevalence of Low Testosterone Levels in Men With Type 2 Diabetes Mellitus: A Cross-Sectional Study. J Fam Community Med (2013) 20:179–86. doi: 10.4103/2230-8229.122006
12. Hofman A, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A, Ikram MA, et al. The Rotterdam Study: 2014 Objectives and Design Update. Eur J Epidemiol (2013) 28:889–926. doi: 10.1007/s10654-013-9866-2
13. Erbay G, Senol G, Anar C, Meral AR, Tuzel O. Relationship Between Tuberculosis and Female Hormone Levels in Post-Menopausal. Southeast Asian J Trop Med Public Health (2016) 47:78–83.
14. De la Chesnaye E, Manuel-Apolar R, Zarate A, Damasio L, Espino N, Revilla-Monsalve MC, et al. Lipocortin-2 Plasatic Levels Are Reduced in Patients With Long-Term Type 2 Diabetes Mellitus. Int J Clin Exp Med (2015) 8:2835–9.
15. Pavan Kumar N, Nair D, Banurekha VV, Dolla C, Kumaran P, Sridhar R, et al. Type 2 Diabetes Mellitus Coincident With Pulmonary or Latent Tuberculosis Results in Modulation of Adipocytokines. Cytokine (2014) 79:74–81. doi: 10.1016/j.cytok.2015.12.026
16. Chia CW, Odentunde JO, Kim W, Carlson OD, Ferrucci L, Egan JG. GIP Contributes to Islet Trihormonal Abnormalities in Type 2 Diabetes. J Clin Endocrinol Metab (2014) 99:2477–85. doi: 10.1210/jc.2013-3994
17. Poytko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O. Low Plasma Ghrelin Is Associated With Insulin Resistance, Hypertension, and the Prevalence of Type 2 Diabetes. Diabetes (2003) 52:2546–53. doi: 10.2337/diabetes.52.10.2546
18. Zheng Y, Ma A, Wang Q, Han X, Cai J, Schouten EG, et al. Relation of Leptin, Ghrelin and Inflammatory Cytokines With Body Mass Index in Pulmonary Tuberculosis Patients With and Without Type 2 Diabetes Mellitus. PLoS One (2013) 8:e80122. doi: 10.1371/journal.pone.0080122
19. Chang SW, Pan WS, Beltran DL, Baldelomar LO, Solano MA, Tueru I, et al. Gut Hormones, Appetite Suppression and Cachexia in Patients With Pulmonary TB. PLoS One (2013) 8:e45564. doi: 10.1371/journal.pone.0045564
20. Omar-Hmeadi M, Lund P-E, Gandasi NR, Tengholm A, Barg S. Paracrine Control of a-Cell Glucagon Exocytosis Is Compromised in Human Type-2 Diabetes. Nat Commun (2020) 11:1896. doi: 10.1038/s41467-020-15717-8
21. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology – Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan – 2015 — Executive Summary. Endocr Pract (2015) 21:413–37. doi: 10.4158/EP15672.GL

FUNDING

This study was supported by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and the South African Medical Research Council under the US-South African Program for Collaborative Biomedical Research (grant number R01AI116039). TW was funded by the National Research Foundation of South Africa. The content is solely the responsibility of the authors and does not necessarily represent the official view of any of the funding agencies.
30. Kumari UR, Padma K. Dehydroepiandrosterone Levels in Type 2 Diabetes. *Int J Med Res Health Sci* (2014) 3:411–5. doi: 10.5958/j.2319-5886.s.2013.083

31. Fernández RDV, Díaz A, Bongiovanni G, Gallucci G, Bértola D, Gardén E, et al. Evidence for a More Disrupted Immune-Endocrine Relation and Cortisol Immunologic Influences in the Context of Tuberculosis and Type 2 Diabetes Comorbidity. *Front Endocrinol* (2020) 11:1126. doi: 10.3389/fendo.2020.01126

32. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and Treatment of Type 2 Diabetes: Perspectives on the Past, Present and Future. *Lancet* (2014) 383:1068–83. doi: 10.1016/S0140-6736(13)62154-6

33. Lee ZS, Chan JC, Yeung VT, Chow CC, Lau MS, Ko GT, et al. Plasma Insulin, Growth Hormone, Cortisol, and Central Obesity Among Young Chinese Type 2 Diabetic Patients. *Diabetes Care* (1999) 22:1450–7. doi: 10.2337/diacare.22.9.1450

34. Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Cheam-Graham C, Holt T, et al. The Comorbidity Burden of Type 2 Diabetes Mellitus: Patterns, Clusters and Predictions From a Large English Primary Care Cohort. *BMC Med* (2019) 17:145. doi: 10.1186/s12916-019-1373-y

35. Champaneri S, Wand GS, Malhotra SS, Casagrande SS, Golden SH. Correlation Between Circulating Corticotropin Releasing Hormone Receptors Type I and Type II mRNA in Suicide Victims and Controls. *Mol Psychiatry* (2001) 6:540–6. doi: 10.1038/sj.mp.4000998

36. Gonzales XF, Deshmukh A, Pulse M, Johnson K, Jones HP. Stress-Induced Differences in Primary and Secondary Resistance Against Bacterial Sepsis Corresponds With Diverse Corticotropin Releasing Hormone Receptor Expression by Pulmonary CD11c+ MHC II+ and CD11c+ MHC II+ APCs. *Brain Res Immunol* (2008) 22:553–60. doi: 10.1016/j.brainresimmunol.2007.11.005

37. Kim B-J, Kayembe K, Simecka JW, Pulse M, Jones HP. Corticotropin Releasing Hormone Receptor-1 and 2 Activity Promotes Divergent Resistance Against Stress-Induced Pulmonary Streptococcus Pneumoniae Infection. *J Neuroimmunol* (2011) 237:57–65. doi: 10.1016/j.jneuroim.2011.06.016

38. Burnley B P, Jones H. Corticotropin-Releasing Hormone Improves Survival in Pneumococcal Pneumonia by Reducing Pulmonary Inflammation. *Physiol Rep* (2017) 5:e13000. doi: 10.14814/phy2.13000

39. Moffatt JD, Lever R, Page CP. Activation of Corticotropin-Releasing Factor-2 Causes Bronchoconstriction and Inhibits Pulmonary Inflammation in Mice. *FASEB J* (2006) 20:1877–9. doi: 10.1096/fj.06-5515jie

40. Brzozka T, Luger TA, Maaser C, Abels C, Boehm M. α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antinflammatory and Protective Effects In Vitro and In Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases. *Endocr Rev* (2008) 29:581–602. doi: 10.1210/er.2007-0007

41. Montero-Melendez T. ACTH: The Forgotten Therapy. *Semin Immunol* (2015) 27:216–26. doi: 10.1016/j.smim.2015.02.003

42. Raap U, Brzozka T, Sohl S, Päth G, Eimmel J, Herz U, et al. α-Melanocyte-Stimulating Hormone Inhibits Allergic Airway Inflammation. *J Immunol* (2003) 171:353–9. doi: 10.4049/jimmunol.171.1.353

43. Colombo G, Gatti S, Sordi A, Turcatti F, Carlin A, Rossi C, et al. Production and Effects of α-Melanocyte-Stimulating Hormone During Acute Lung Injury. *Shock* (2007) 27:326–33. doi: 10.1097/01.shk.0000239764.80033.7e

44. Deng J, Hu X, Yue PT, Star RA. Alpha-Melanocyte-Stimulating Hormone Inhibits Lung Injury After Renal Ischemia/Reperfusion. *Am J Respir Crit Care Med* (2004) 169:749–56. doi: 10.1164/rccm.200303-372OC

45. Ericson MD, Lensing CJ, Fleming KA, Schlaser KN, Doering SR, Haskell-Luevano C. Bench-Top to Clinical Therapies: A Review of Melanocortin Ligands From 1954 to 2016. *Biochim Biophys Acta BBA Mol Basis Dis* (2017) 1863:2414–35. doi: 10.1016/j.bbadis.2017.03.020

46. Zhang C, Tain T, Cai R, Wanggauchitch M, Mirsaedi M, Schally AV, et al. Growth Hormone-Modulating Hormone in Lung Physiology and Pulmonary Disease. *Celsi* (2020) 9:2331. doi: 10.3390/cells9102331

47. Christodoulou C, Schally AV, Chatzistamou I, Koudi-Pafihi A, Lannissou K, Koulouberi S, et al. Expression of Growth Hormone-Released Hormone (GHRH) and Splice Variant of GHRH Receptors in Normal Mouse Tissues. *Regul Pept* (2006) 136:105–8. doi: 10.1016/j.regpept.2005.05.001

48. Uddin MA, Akhter MS, Singh SS, Kubra KT, Schally AV, Jois S, et al. GHRH Antagonists Support Lung Endothelial Barrier Function. *Tissue Barriers* (2019) 7:1669989. doi: 10.2117/18688370.2019.1669989

49. Zhang C, Cai R, Lazerson A, Delcroix G, Wanggauchitch M, Mirsaedi M, et al. Growth Hormone-Released Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis Due to Bleomycin. *Lung* (2019) 197:541–9. doi: 10.1007/s00135-019-00257-w

50. Zhang C, Tian R, Dreifus EM, Holt G, Cai R, Grisswold A, et al. Activity of the GHRH Antagonist MIA602 and Its Underlying Mechanisms of Action in Inflammation and Aging. *Clin TranslATIONAL Med* (2017) 5:e1310. doi: 10.1002/cti.1310

51. Farhat K, Bodart G, Charlet-Renard C, Desmet CJ, Moutschen M, Beguin Y, et al. Growth Hormone (GH) Deficient Mice With GHRH Gene Ablation Are Severely Deficient in Vaccine and Immune Responses Against Streptococcus Pneumoniae. *Front Immunol* (2018) 9:2173. doi: 10.3389/fimmu.2018.02175

52. Liu Z, Yu Y, Jiang Y, Li J. Growth Hormone Increases Circulating Neutrophil Activation and Provokes Lung Microvascular Injury in Septic Peritonitis Rats. *J Surg Res* (2002) 105:195–9. doi: 10.1006/jscr.2002.6374

53. Liu Z-H, Yu Y-Q, Li W-Q, Li J-S. Growth Hormone Increases Lung Microvascular Injury in Lipopolysaccharide Peritonitis Rats: Possible Involvement of NF-kappab Activation in Circulating Neutrophils. *Acta Pharmacol Sin* (2002) 23:887–92.

54. Yi C, Wang SR, Zhang SY, Yu SJ, Jiang CX, Zhi MH, et al. Effects of Recombinant Human Growth Hormone on Acute Lung Injury in Endotoxemic Rats. *Inflammation Res* (2006) 55:491–7. doi: 10.1007/s00011-006-6011-4

55. Yi C, Cao Y, Mao SH, Liu H, Ji LL, Xu SY, et al. Recombinant Human Growth Hormone Improves Survival and Protects Against Acute Lung Injury in Murine Staphylococcus Aureus Sepsis. *Inflamm Res* (2009) 58:855–62. doi: 10.1007/s00011-009-0506-0

56. Kühn ER, Bellon K, Huybrechts L, Heyns W. Endocrine Differences Between the Wistar and Sprague-Dawley Laboratory Rat: Influence of Cold Adaptation. *Horm Metab Res Horm Stoffwechselforschung Horm Metab* (1983) 15:491–8. doi: 10.1055/s-2007-1018767

57. Suzuki T, Sasano H, Suzuki S, Hirasega G, Takeyama J, Muramatsu Y, et al. 11Beta-Hydroxysteroid Dehydrogenase Type 2 in Human Lung: Possible Regulator of Mineralocorticoid Action. *J Clin Endocrinol Metab* (1998) 83:4022–5. doi: 10.1210/jcem.83.11.5227
67. Miravitles M, Auladell-Rispeu A, Monteagudo M, Vázquez-Niebla JC, Mohammed J, Nuñez A, et al. Systematic Review on Long-Term Adverse Effects of Inhaled Corticosteroids in the Treatment of COPD. Eur Respir Rev (2020) 30:210075. doi: 10.1183/16000617.0075-2021

68. Lu S-F, Mo Q, Hu S, Garippa C, Simon NG. Dehydroepiandrosterone Upregulates Neural Androgen Receptor Level and Transcriptional Activity. J Neurobiol (2003) 57:163–71. doi: 10.1002/neu.10260

69. Webb SJ, Geoghegan TE, Prough RA, Miller KKM. The Biological Actions of Dehydroepiandrosterone Involves Multiple Receptors. Drug Metab Rev (2006) 38:89–116. doi: 10.1080/03602530600569877

70. Oka M, Karoor V, Homma N, Nagaoka T, Sakao E, Godelmisc SM, et al. Dehydroepiandrosterone Upregulates Soluble Guanylate Cyclase and Inhibits Hypoxic Pulmonary Hypertension. Cardiovasc Res (2007) 74:377–84. doi: 10.1016/j.cardiores.2007.01.021

71. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S. Dehydroepiandrosterone Inhibits the Src/STAT3 Constitutive Activation in Pulmonary Arterial Hypertension. Am J Physiol Heart Circ Physiol (2011) 301:H1798–1809. doi: 10.1152/ajpheart.00654.2011

72. Corsini E, Lucchi L, Meroni M, Lucchi L, Racchi M, SOLerte B, Fioravanti M, et al. DHEA Significantly Inhibits the Constitutive Activation of STAT3 in Alveolar Epithelial Cells. Tissue-Based Map of the Human Proteome. Tissue-Based Map of the Human Proteome.

73. Webb SJ, Geoghegan TE, Prough RA, Miller KKM. The Biological Actions of Dehydroepiandrosterone Involves Multiple Receptors. Drug Metab Rev (2006) 38:89–116. doi: 10.1080/03602530600569877

74. Oka M, Karoor V, Homma N, Nagaoka T, Sakao E, Godelmisc SM, et al. Dehydroepiandrosterone Upregulates Soluble Guanylate Cyclase and Inhibits Hypoxic Pulmonary Hypertension. Cardiovasc Res (2007) 74:377–84. doi: 10.1016/j.cardiores.2007.01.021

75. Shahrara S, Drvota V, Sylven C. Organ Specific Effects of Thyroid Hormones in Asthma. Endocrinol](2015) 347:1260419. doi: 10.1126/science.1260419

76. Shang R, Lei J, Mariash CN, Bhargava M, Wattenberg EV, Ingbar DH. T3 Increases MUC5AC Expression and Alveolar Epithelial Cell Density with a Peak at 7 days in the Neonatal Rat Lung. Am J Physiol-Lung Cell Mol Physiol (2010) 308:L108–115. doi: 10.1152/ajplung.00335.2007

77. Ming S, Wu J, Ma J, Gao X, Xiao L, He X, et al. The Effects of DHEA on the Expression of Oestrogen Receptors in Different Human Tissues. Menopause (2021) 28:450–58. doi: 10.1097/gme.0000000000001533

78. Smith DM, Hitchcock KR. Thyroid Hormone Binding to Adult Rat Alveolar Type II Cells. An Autoradiographic Study. Exp Lung Res (1983) 5:141–5. doi: 10.3109/190018403900001610

79. Morishige WK. Thyroid Hormone Inhibits the Spontaneous Release of Superoxide Radical by Alveolar Macrophages In Vitro in Asbestosis. Environ Res (1991) 55:145–56. doi: 10.1016/0013-9351(93)80179-9

80. Choi IS, Cui Y, Koh Y-A, Lee H-C, Cho Y-B, Won Y-H. Effects of Dehydroepiandrosterone on Th2 Cytokine Production in Peripheral Blood Mononuclear Cells From Asthmatics. Korean J Intern Med (2008) 23:176–81. doi: 10.3904/kjim.2008.23.4.176

81. Lei J, Mariash CN, Bhargava M, Wattenberg EV, Ingbar DH. T3 Increases MUC5AC Expression and Alveolar Epithelial Cell Density with a Peak at 7 days in the Neonatal Rat Lung. Am J Physiol-Lung Cell Mol Physiol (2010) 308:L108–115. doi: 10.1152/ajplung.00335.2007

82. Ning Y, Zhang M, Du Y-H, Zhang H-N, Li L-Y, Qin Y-W, et al. Effects of Dehydroepiandrosterone on Th2 Cytokine Production in Peripheral Blood Mononuclear Cells From Asthmatics. Korean J Intern Med (2008) 23:176–81. doi: 10.3904/kjim.2008.23.4.176

83. Barca-Mayo O, Liao X-H, DiCosmo C, Dumitrescu A, Moreno-Vinasco L, Wade –pez-Torres MO, Marquina-Castillo B, Ramos-Espinosa O, Mata-Espinosa

84. Vieira Braga FA, Kar G, Berg M, Carpaij OA, Polanski K, Simon LM, et al. Estrogen Receptor-α as a Drug Target Candidate for Preventing Lung Inflammation. Endocrinology (2010) 151:174–84. doi: 10.1210/en.2009-0876

85. Knapczyk K, Porcine FB, Wolsza K, Panasiewicz G, Koziorowski M, et al. Immunolocalisation of Oestrogen Receptors Alpha (Ere) and Beta (Erb) in Porcine Embryos and Fetuses at Different Stages of Gestation. Acta Vet Hung (2008) 56:221–33. doi: 10.1556/avet.56.2008.2.10

86. Beyer C, Küppers E, Karpacz J, Trotter A. Ontogenetic Expression of Estrogen Receptors and Progestosterone Receptors in the Mouse Lung. Neonatology (2003) 84:59–63. doi: 10.1159/000071445

87. Vieira Braga FA, Kar G, Berg M, Carpaij OA, Polanski K, Simon LM, et al. Estrogen Receptor-α as a Drug Target Candidate for Preventing Lung Inflammation. Endocrinology (2010) 151:174–84. doi: 10.1210/en.2009-0876

88. Nogi Y, Nagashima M, Terasaki M, Notomi K, Watanabe T, Hirano T. Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice. PLoS One (2012) 7:e35683. doi: 10.1371/journal.pone.0035683

89. Kahles F, Liberman A, Halim C, Rau M, Möllmann J, Mertens RW, et al. The Increrin Hormone GIP is Upreregulated in Patients With Atherosclerosis and Stabilizes Plaques in ApoE–/– Mice by Blocking Monocyte/Macrophage Activation. Mol Metab (2018) 14:150–7. doi: 10.1016/j.molmet.2018.05.014

90. Duply JL, Ferguson RF, Fuller PJ. Tissue Distribution of Rat Glucagon Receptor and GLP-1 Receptor Gene Expression. Mol Cell Endocrinol (1998) 141:179–86. doi: 10.1016/s0303-7207(98)00096-3

91. Vibe N-E, Isidor MS, Buggesskov KB, Poulsen SS, Hansen JB, Kissow H. Glucagon-Like Peptide-1 (GLP-1) Reduces Mortality and Improves Lung Function in a Model of Experimental Obstructive Lung Disease in Female Mice. Endocrinology (2013) 154:4503–11. doi: 10.1210/en.2013-1666

92. Lee Y-S, Jun H-S. Anti-Inflammatory Effects of GLP-1-Based Therapies Beyond Glucose Control. Mediators Inflamm (2016) 2016:3094642. doi: 10.1155/2016/3094642

93. Zhu T, Wu X, Zhang W, Xiao M. Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-xb (NF-xb) Signaling Pathway in Mice. Int J Mol Sci (2015) 16:20195–211. doi: 10.3390/ijms160920195

94. Gou S, Zhu T, Wang W, Xiao M, Wang X, Chen Z. Glucagon Like Peptide-1 Attenuates Bleomycin-Induced Pulmonary Fibrosis, Involving the Inactivation of NF-kb in Mice. Int Immunopharmacol (2014) 22:498–504. doi: 10.1016/j.intimp.2014.07.010

95. Valk Moller E, Windelov JA, Svendsen B, Hunt J, Ghiassi SM, Sørensen CM, et al. Glucagon-Like Peptide 1 and Atrial Natriuretic Peptide in a Female Mouse Model of Obstructive Pulmonary Disease. J Endocr (2019) 4: bvez034. doi: 10.1210/endo/bvez034
105. Hosokawa S, Haraguchi G, Maejima Y, Doi S, Isobe M. Abstract 13355: The Synergistic Effects of Incretin-Related Drugs for the Treatment of Pulmonary Arterial Hypertension. Circulation (2014) 130:A13355–5. doi: 10.1161/ cirkulationaha.113.008308.2010

106. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin Is a Growth-Hormone-Releasing Acylated Peptide From Stomach. Nature (1999) 402:656–60. doi: 10.1038/45230

107. Kitazawa T, Nakamura T, Sacki A, Teraoka H, Hiraga T, Kaiya H. Molecular Identification of Ghrelin Receptor (GHS-R1a) and Its Functional Role in the Gastrointestinal Tract of the Guinea-Pig. Peptides (2011) 32:1876–86. doi: 10.1016/j.peptides.2010.07.026

108. Sun Y, Garcia JM, Smith RG. Ghrelin and Growth Hormone Secretagogue Receptor Expression in Mice During Aging. Endocrinology (2007) 148:1323– 9. doi: 10.1210/en.2006-0782

109. Ghelardoni S, Carnicelli V, Frascarcelli S, Ronca-Testoni S, Zucchi R. Ghrelin Tissue Distribution: Comparison Between Gene and Protein Expression. J Endocrinol Invest (2006) 29:115–21. doi: 10.1007/BF03344083

110. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, et al. The Tissue Distribution of the mRNA of Ghrelin and Subtypes of Its Receptor, GHS-R, in Humans. J Clin Endocrinol Metab (2002) 87:2988–91. doi: 10.1210/jcem.87.7.8737

111. Volante M, Fulcheri E, Alle A, Cerrato M, Pucci A, Papotti M. Ghrelin Expression in Fetal, Infant, and Adult Human Lung. J Histochem Cytochem (2002) 50:1013–21. doi: 10.1177/002215540205000808

112. Ueberberg B, Unger N, Saeger W, Mann K, Petersenn S. Expression of Ghrelin and Its Receptor in Human Tissues. Tissue Biol (2009) 41:814– 21. doi: 10.1055/s-0029-1233462

113. Peng Z, Zhu Y, Zhang Y, Wilhelmsen K, Jia C, Jin J, et al. Effects of Ghrelin on Pulmonary NOD2 mRNA Expression and NF-κB Activation When Protects Against Acute Lung Injury in Rats Challenged With Cecal Ligation and Puncture. Int Immunopharmacol (2012) 13:440–5. doi: 10.1016/j.intimp.2012.04.006

114. Harvey RE, Howard VG, Lemus MB, Jois T, Andrews ZB, Sleeman MW. The Ghrelin/GOAT System Regulates Obesity-Induced Inflammation in Male Mice. Endocrinology (2017) 158:2179–89. doi: 10.1210/en.2016-1832

115. Liu H, Luo J, Guillyoud B, Chen J, Zang P, Yoeli JK, et al. (In-Gi), Anderson B, Storie M, Et al. Ghrelin Ameliorates Tumor-Induced Adipose Tissue Atrophy and Inflammation via Ghrelin Receptor-Dependent and -Independent Pathways. Oncotarget (2020) 11:3286–302. doi: 10.18632/ oncotarget.27705

116. Li B, Zeng M, He W, Huang X, Luo L, Zhang H, et al. Ghrelin Protects Alveolar Macrophages Against Lipopolysaccharide-Induced Apoptosis Through Growth Hormone Secretagogue Receptor 1a-Dependent C-Jun N-Terminal Kinase and Wortmannin Signaling and Suppresses Lung Inflammation. Endocrinology (2015) 156:203–17. doi: 10.1210/en.2014-1539

117. Wu R, Dong W, Zhou M, Zang F, Marini CP, Ravikumar TS, et al. Ghrelin Attenuates Sepsis-Induced Acute Lung Injury and Mortality in Rats. Am J Respir Crit Care Med (2007) 176:805–13. doi: 10.1164/rccm.200604-511OC

118. Rocha N de N, de Oliveira MV, Braga CL, Guimarães G, de Albuquerque Yosten GLC, Kolar GR, Redlin ger LJ, Samson WK. Evidence for an Inflammation, and Remodeling Induced by Ovalbumin. Am J Physiol Lung Cell Mol Physiol (2004) 287:H2885–90. doi: 10.1152/ajplung.00122.2003

119. Henriques-Coelho T, Correia-Pinto J, Roncon-Albuquerque R, Baptista MJ, Redlin ger LJ, Samson WK. Evidence for an Inflammation, and Remodeling Induced by Ovalbumin. Am J Physiol Lung Cell Mol Physiol (2004) 287:H2885–90. doi: 10.1152/ajplung.00122.2003

120. Ye R, Scherer PE. Adiponectin, Driver or Passenger on the Road to Insulin Sensitivity? Mol Med (2013) 21:339–41. doi: 10.1016/j.molmed.2013.04.001
143. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of Adiponectin Receptors That Mediate Anti-diabetic Metabolic Effects. *Nature* (2003) 423:762–9. doi: 10.1038/nature01705

144. Shore SA, Terry RD, Flynn L, Xu A, Hug C, Kong H. Adiponectin Attenuates Inflammation and Hyperresponsiveness in Mice. *J Allergy Clin Immunol* (2006) 118:389–95. doi: 10.1016/j.jaci.2006.04.021

145. Amaraaikh N, Tsoogerel A, Hug C, Templton SP. The Metabolic Cytokine Adiponectin Inhibits Inflammatory Lung Pathology in Invasive Aspergillosis. *J Immunol* (2019) 203:956–63. doi: 10.4049/jimmunol.1900174

146. Garcia P, Sood A. Adiponectin in Pulmonary Disease and Critically Ill Patients. *Curr Med Chem* (2012) 19:5493–500. doi: 10.2174/09298671280335263

147. Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, Gokce N, et al. Adiponectin Promotes Macrophage Polarization Toward an Anti-Inflammatory Phenotype. *J Biol Chem* (2010) 285:6155–60. doi: 10.1074/jbc.M109.088708

148. Yamashita T, Lakota K, Taniguchi T, Yoshizaki A, Sato S, Hong W, et al. Suzukawa M, Koketsu R, Baba S, Igarashi S, Nagase H, Yamaguchi M, et al. Expression of Lipocalin-2 Is Required for Pulmonary Host Defense Against Klebsiella Pneumoniae. *J Immunol* (2009) 182:9497–56. doi: 10.4049/jimmunol.0803282

149. Li B, Fang I, Zuo Z, Yin S, He T, Yang M, et al. Activation of the Porcine Alveolar Macrophages via Toll-Like Receptor 4/NF-κB Mediated Pathway Provides a Mechanism of Resistin Leading to Inflammation. *Cytokine* (2018) 110:357–66. doi: 10.1016/j.cytokine.2018.04.002

150. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI. Resistin Competes With Lipopolysaccharide for Binding to Toll-Like Receptor 4. *J Cell Mol Med* (2010) 14:1419–31. doi: 10.1111/j.1582-4934.2009.00899.x

151. Planès C, Leyrroz C, Uchida T, Angelova MA, Vaugniaux G, Hummeler M, et al. In Vitro and In Vivo Regulation of Transcriptal Pulmonary Alveolar Sodium Transport by Serine Proteases. *Am J Physiol-Lung Cell Mol Physiol* (2005) 288:L1099–109. doi: 10.1152/ajplung.00332.2004

152. Zhao C-W, Gao Y-H, Song W-X, Liu B, Ding L, Dong N, et al. An Update on the Emerging Role of Resistin on the Pathogenesis of Osteoarthritis. *Mediators Inflammation* (2019) 2015:132164. doi: 10.1155/2019/1532164

153. Jiang S, Park DW, Tedie J-M, Gregoire M, Deshane J, Piett JF, et al. Human Resistin Promotes Neutrophil Pro-Inflammatory Activation, Neutrophil Extracellular Trap Formation, and Increases Severity of Acute Lung Injury. *J Immunol* (2014) 192:7495–803. doi: 10.4049/jimmunol.1302764

154. Wang W-Y, Chen Y, Su X, Tung D, Ben Q-W, Yao W-Y, et al. Resistin-Like Molecule-α Causes Lung Injury in Rats With Acute Pancreatitis by Activating the PI3K/Akt/NF-κB Pathway and Promoting Inflammatory Cytokine Release. *Curr Mol Med* (2016) 16:677–87. doi: 10.2174/15665240166661802145700

155. Mishra A, Wang M, Schlotman J, Nikoladis NM, DeBrosse CW, Karow ML, et al. Resistin-Like Molecule-Beta is an Allergen-Induced Cytokine With Inflammatory and Remodeling Activity in the Murine Lung. *Am J Physiol-Lung Cell Mol Physiol* (2007) 293:L305–313. doi: 10.1152/ajplung.00147.2007

156. Meng L, Li L, Lu S, Li K, Su Z, Wang Y, et al. The Protective Effect of Dexamethasone on LPS-Induced Acute Lung Injury Through the HMGB1-Mediated TL1A/NF-κB and PI3K/Akt/mTOR Pathways. *Mol Immunol* (2018) 947–17. doi: 10.1016/j.molimm.2017.12.008

157. Ye R, Liu Z, ACE2 Exhibits Protective Effects Against LPS-Induced Acute Lung Injury in Mice by Inhibiting the LPS-TLR4 Pathway. *Exp Mol Pathol* (2020) 113:104350. doi: 10.1016/j.yexmp.2019.104350

158. Fuentes N, Silveyra P. Endocrine Regulation of Lung Disease and Inflammation. *Exp Biol Med* (2018) 243:1313–22. doi: 10.1177/1933948318767506

159. Zammit C, Liddicote H, Moonsie I, Makker H. Adiponectin Attenuates Chemotaxis and Cytokine Secretion. *J Invest Dermatol* (2016) 136:1418–28. doi: 10.1111/jid.2016.03.002

160. Wang Q, Li S, Tang X, Liang L, Wang F, Du H. Lipocalin 2 Protects Against Escherichia Coli Infection by Modulating Neutrophil and Macrophage Function. *Front Immunol* (2019) 10:2594. doi: 10.3389/fimmu.2019.02594

161. Gugliani L, Gopal R, Rangel-Moreno I, Junecko BF, Lin Y, Berger T, et al. Lipocalin 2 Regulates Inflammation During Pulmonary Mycobacterial Infections. *PLoS One* (2012) 7:e50052. doi: 10.1371/journal.pone.0050052

162. Chan YR, Liu JS, Pociask DA, Zheng M, Mietzner TA, Berger T, et al. Lipocalin 2 Is Required for Pulmonary Host Defense Against Klebsiella Pneumoniae. *J Immunol* (2009) 182:9497–56. doi: 10.4049/jimmunol.0803282
183. de Martino M, Lodi L, Galli L, Chiappini E. Immune Response to Mycobacterium Tuberculosis: A Narrative Review. *Front Pediatr* (2019) 7:350. doi: 10.3389/fped.2019.00350

184. Kumar Nathella P, Babu S. Influence of Diabetes Mellitus on Immunity to Human Tuberculosis. *Immunology* (2017) 152:13–24. doi: 10.1111/imm.12762

185. Ayelign B, Negash M, Genetu M, Wondmagegn T, Shibabaw T. Immunological Impacts of Diabetes on the Susceptibility of Mycobacterium Tuberculosis. *J Immunol Res* (2019) 2019:e6196532. doi: 10.1155/2019/6196532

186. Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System. *Front Immunol* (2020) 11:1582. doi: 10.3389/fimmu.2020.01582

187. Jiménez-Corona ME, Cruz-Hervert LP, García-García L, Ferreyra-Reyes L, Delgado-Sánchez G, Bobadilla-del-Valle M, et al. Association of Diabetes and Tuberculosis: Impact on Treatment and Post-Treatment Outcomes. *Thorax* (2013) 68:214–20. doi: 10.1136/thoraxjnl-2012-201756

188. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff THM, et al. The Effect of Type 2 Diabetes Mellitus on the Presentation and Treatment Response of Pulmonary Tuberculosis. *Clin Infect Dis* (2007) 45:428–35. doi: 10.1086/519841

189. Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The Impact of Diabetes on Tuberculosis Treatment Outcomes: A Systematic Review. *BMJ Med* (2011) 9:81. doi: 10.1186/1741-7015-9-81

190. Gil-Santana L, Almeida-Junior JL, Oliveira CAM, Hickson LS, Daltro C, Castro S, et al. Diabetes Is Associated With Worse Clinical Presentation in Tuberculosis Patients From Brazil: A Retrospective Cohort Study. *PLoS One* (2016) 11:e0146876. doi: 10.1371/journal.pone.0146876

191. World Health Organization. *WHO Report on Surveillance of Antibiotic Consumption* Vol. 45. Geneva: World Health Organization (2018).

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Webber, Ronacher, Conradie-Smit and Kleynhans. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.